Haemonetics Corporation (HAE) Stock Price & Analysis
Haemonetics Corporation (HAE) closed at USD 116.16 on Thursday, October 22, 2026, down 0.81% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 117.11; the Oct 22, 2026 session ranged USD 116.07–118.68 on volume of 365,124 shares. Market capitalization is $5.28B, with a 52-week range of USD 48.98–123.77 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HAE.md
Key facts (HAE)
- Last four reported quarters (through Jun 27, 2026): revenue $1.35B, net income $96.3M (7.1% margin), free cash flow $291M (SEC filings).
- Valuation: P/E 54.9x (avg 28.0x at the last 3 fiscal year-ends), EV/EBITDA 23.1x, net debt $965M.
- 1 of 80 tracked superinvestors hold HAE (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.82 on a 1–5 scale) (11 analysts), mean target USD 124.5 (range 86–142).
- Total return with dividends: 1Y +126.2% vs S&P 500 +14.9%; 5Y +61.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.29, revenue estimate $345M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HAE)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $993M | $1.17B | $1.31B | $1.36B | $1.33B | $1.35B |
| Gross profit | $506M | $615M | $692M | $749M | $788M | — |
| Operating income | $80.8M | $156M | $165M | $222M | $157M | $160M |
| Net income | $43.4M | $115M | $118M | $168M | $97.3M | $96.3M |
| EPS (diluted) | $0.84 | $2.24 | $2.29 | $3.31 | $2.05 | — |
| Free cash flow | $75.8M | $81.7M | $144M | $142M | $260M | $291M |
| Gross margin | 50.9% | 52.6% | 52.8% | 55.0% | 59.0% | — |
| Operating margin | 8.1% | 13.4% | 12.6% | 16.3% | 11.7% | 11.9% |
| Net margin | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% | 7.1% |
| Revenue growth | +14.1% | +17.7% | +12.0% | +4.0% | -2.0% | — |
| Cash + short-term investments | $259M | $284M | $179M | $307M | $245M | — |
| Total debt | $774M | $766M | $808M | $1.22B | $1.24B | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 27, 2026) (HAE)
P/E 54.9x · P/S 3.9x · EV/EBITDA 23.1x · EV/Sales 4.6x · P/FCF 18.1x · P/B 6.3x · FCF yield 5.51% · Earnings yield 1.82% · Net debt $965M · EV $6.25B
P/E at fiscal year-ends: Mar 2026 27.4x, Mar 2025 19.2x, Mar 2024 37.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (HAE)
1 of 80 tracked investors hold HAE. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 1.54% | $155M | New position |
Analysts (HAE)
Consensus Buy (mean 1.82 on a 1–5 scale), 11 analysts; mean target USD 124.5 (low 86, high 142).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Barrington Research | Target raised | Outperform | $118 → $140 |
| 2026-10-09 | Mizuho | Target raised | Outperform | $95 → $140 |
| 2026-10-08 | BTIG | Target raised | Buy | $110 → $130 |
| 2026-09-17 | Citigroup | Upgrade | Neutral → Buy | $92 → $123 |
| 2026-09-03 | Raymond James | Target raised | Outperform | $105 → $125 |
| 2026-08-21 | Baird | Target raised | Outperform | $96 → $119 |
| 2026-08-19 | Barrington Research | Target raised | Outperform | $95 → $118 |
| 2026-08-18 | BTIG | Target raised | Buy | $96 → $110 |
| 2026-08-07 | Citigroup | Target raised | Neutral | $79 → $92 |
| 2026-08-07 | JP Morgan | Target raised | Neutral | $62 → $86 |
| 2026-08-06 | BTIG | Target raised | Buy | $84 → $96 |
| 2026-07-15 | Mizuho | Target raised | Outperform | $85 → $90 |
Total return (dividends reinvested) (HAE)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +126.2% | +61.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +126.8% | +10.1% |
| Volatility (annualized) | 48.3% | 43.2% |
| Max drawdown | -40.1% (Dec 2025→May 2026) | -49.8% (May 2024→Sep 2025) |
HAE revenue by business segment (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Apheresis | $191.3M | 56.4% | +5.3% |
| MedSurg | $148.1M | 43.6% | +6.0% |
| Total revenue | $339.4M | 100% | — |
HAE revenue by product line (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Plasma | $155.5M | 45.8% | +7.2% |
| Blood Management Technologies | $88.1M | 26.0% | +8.6% |
| Interventional Technologies | $59.9M | 17.7% | +2.5% |
| Other | $35.8M | 10.5% | -2.4% |
| Total revenue | $339.4M | 100% | — |
HAE revenue by region (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| UNITED STATES | $257.8M | 76.0% | +6.4% |
| Europe | $45.5M | 13.4% | +11.4% |
| Rest of Asia | $20.2M | 5.9% | -6.9% |
| Japan | $12.9M | 3.8% | -5.8% |
| Other | $3.0M | 0.9% | +6.2% |
| Total revenue | $339.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
HAE suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Offshore International | “In addition, we manufacture our VASCADE vascular closure devices under a shelter plan service agreement with Offshore International Incorporated (d/b/a Tetakawi) pursuant to which we lease our manufacturing facility in Guaymas, Mexico.” |
| Partner | Vivasure Medical | “We have sought and in the future may seek to supplement our organic growth through strategic acquisitions, investments and alliances, including our acquisitions of Vivasure Medical Limited, OpSens Inc. and Attune Medical.” |
| Partner | OpSens | “We have sought and in the future may seek to supplement our organic growth through strategic acquisitions, investments and alliances, including our acquisitions of Vivasure Medical Limited, OpSens Inc. and Attune Medical.” |
Quoted from the company's 10-K filed May 20, 2026.
Companies that name HAE in their SEC reports
| Relationship to HAE | Company | Filing | Sentence |
|---|---|---|---|
| partner | Orchestra BioMed Holdings, Inc. (OBIO) | 10-K Mar 12, 2026 | “The amount and timing of our future funding requirements are dependent on many factors, including the cost and pace of execution of clinical studies and research and development activities, the strength of results from clinical studies and other research, development and manufacturing efforts, as well as the potential receipt of revenues or other payments or investments under the Medtronic Agreement and/or future …” |
HAE customer concentration
In the period ended Mar 28, 2026, a single direct customer accounted for 13% of revenue, per the company's 10-K filed May 20, 2026. The company does not name it.
HAE company outlook (results filed Aug 6, 2026)
- “We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value." 1 GAAP RESULTS First quarter fiscal 2027 revenue was $339.4 million, up 5.6% compared with the first quarter of fiscal 2026.”
Quoted word-for-word from the SEC 8-K results press release.
HAE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.29 | $1.27 | +1.3% | $345.1M | 11 |
| Next quarter (ends Dec 2026) | $1.36 | $1.39 | -2.0% | $357.6M | 11 |
| Current fiscal year (ends Mar 2027) | $5.31 | $5.22 | +1.8% | $1.42B | 11 |
| Next fiscal year (ends Mar 2028) | $5.78 | $5.63 | +2.7% | $1.50B | 11 |
HAE options: expected move
Options price a move of about ±11.7% (±$13.65) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±14.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 52.0% | ±11.7% |
| Dec 18, 2026 | 56 | 43.2% | ±13.6% |
| Jan 15, 2027 | 84 | 41.4% | ±15.9% |
| Mar 19, 2027 | 147 | 44.0% | ±22.2% |
| Jun 17, 2027 | 237 | 43.4% | ±27.8% |
30-day implied volatility 47.5% vs 50.7% realized over the last 30 trading days. Put/call ratio (volume) 1. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 116.16 |
|---|---|
| Change | ▼ 0.81% (down) |
| Previous Close | USD 117.11 |
| Open | USD 117.7 |
| Day Range | USD 116.07 – 118.68 |
| 52-Week Range | USD 48.98 – 123.77 |
| Volume | 365,124 shares |
| Market Cap | $5.28B |
| Exchange | NYQ |
Technical Analysis (HAE)
Nexqual's technical model rates HAE "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.73 (neutral) |
| vs SMA50 | Above (USD 107.52) |
| MACD | 3.92 (positive) |
Analyst Ratings (HAE)
Wall Street analysts rate HAE "Buy" based on 11 analysts, with a mean price target of USD 124.5 (range USD 86–142), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 124.5 |
| High Target | USD 142 |
| Low Target | USD 86 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (HAE)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.29 |
| Revenue Estimate | $345.15M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.14 vs est 1.08 ▲ beat |
| 2026-03-31 | USD 1.29 vs est 1.27 ▲ beat |
| 2025-12-31 | USD 1.31 vs est 1.25 ▲ beat |
| 2025-09-30 | USD 1.27 vs est 1.11 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (HAE)
| Total Revenue | $1.35B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.60% |
| Gross Margin | +59.33% |
| Operating Margin | +17.93% |
| Profit Margin | +7.12% |
| ROE | +11.20% |
| Debt / Equity | 1.4 |
| Current Ratio | 3.08 |
| Total Cash | $224.52M |
| Total Debt | $1.17B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $291.22M (21.5% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (HAE)
Nexqual rates Haemonetics Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 18% (last 12 months) |
| Balance Sheet | Mixed — $223M cash and investments vs $1.19B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $291M (last 4 quarters to Jun 2026, SEC), 22% margin |
| Efficiency | Mixed — ROE 11%, ROA 6.6% |
Ownership (HAE)
| Insider Ownership | +1.26% |
|---|---|
| Institutional Ownership | +112.46% |
| Shares Outstanding | 45.50M |
| Float | 44.89M |
| Short % of Float | +7.81% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (HAE)
Haemonetics Corporation is led by Christopher A. Simon, CEO, President & Director, per Nexqual as of October 23, 2026 at 12:51 UTC.
| CEO, President & Director | Christopher A. Simon |
|---|---|
| CFO, Executive VP & Financial Officer | James C. D'Arecca |
| Executive VP & COO | Frank W. Chan |
| Senior Director of Global Communications | Josh Gitelson |
| Senior Vice President of Strategy & Corporate Development | Rajeev Varma |
Major Backers & Investors (HAE)
Notable institutional backers of Haemonetics Corporation include Neuberger Berman Group, LLC, AQR Capital Management, LLC, Ariel Investments, LLC, according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Neuberger Berman Group, LLC | 9.19% |
| AQR Capital Management, LLC | 4.98% |
| Ariel Investments, LLC | 4.53% |
| Citadel | 3.32% |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 1.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.99% |
| Vanguard Group | 10.13% |
| State Street | 4% |
| Dimensional Fund Advisors | 3.48% |
| Geode Capital | 2.83% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From Haemonetics Corporation's Latest SEC 10-K Filing (filed 2026-05-20)
Key Strengths & Strategy (as disclosed to the SEC)
- During fiscal 2026 we announced FDA clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology, which represents the next generation of our proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.
- Food and Drug Administration ("FDA") 510(k) clearance for our NexSys PCS with proprietary Persona® technology.
- In fiscal 2024, we received FDA clearance for advancements to NexSys PCS including a new plasma collection bowl and new Express® Plus technology engineered to reduce procedure time.
- Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.
Partnerships
- In the U.S., allegations of such wrongful conduct could also result in a corporate integrity agreement with the U.S. government that imposes significant administrative obligations and costs.
Legal & Regulatory Risks (Item 1A, quoted)
- Failure to substantially comply with applicable regulations could subject our products to recall or seizure of our products by government authorities, or an order to suspend manufacturing and distribution activities.
- Any future failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA or other regulatory authority could result in administrative actions, field actions, or civil or criminal enforcement actions.
- Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
- The tax regimes we are subject to or operate under are unsettled and may be subject to significant change.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIVN | LivaNova PLC | USD 81.27 | ▲ 3.61% |
| ITGR | Integer Holdings Corporation | USD 126.56 | ▼ 0.11% |
| IRTC | iRhythm Holdings, Inc. | USD 119.64 | ▲ 5.36% |
| BRKR | Bruker Corporation | USD 57.31 | ▼ 3.05% |
| TXG | 10x Genomics, Inc. | USD 69.75 | ▼ 7.73% |
| BIO | Bio-Rad Laboratories, Inc. | USD 363.5 | ▲ 0.83% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt